




Searching News Database: interferon beta-1a
HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
HSMN NewsFeed - 7 Dec 2017
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology & Immunology, US Medical Affairs
HSMN NewsFeed - 4 Dec 2017
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
Merck's Mavenclad (Cladribine Tablets) Approved for Relapsing-Remitting Multiple Sclerosis in Canada
HSMN NewsFeed - 9 Nov 2017
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
HSMN NewsFeed - 28 Jun 2016
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
FDA Grants Priority Review for Genentech’s OCREVUS(TM) (ocrelizumab) Biologics License Application
HSMN NewsFeed - 21 Mar 2014
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Brazil for Treatment of Multiple Sclerosis
HSMN NewsFeed - 30 Dec 2013
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
Genzyme Receives Complete Response Letter from FDA on Lemtrada(TM) (alemtuzumab) Application
HSMN NewsFeed - 19 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Australia for Treatment of Multiple Sclerosis
HSMN NewsFeed - 13 Dec 2013
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
Genzyme’s Lemtrada(TM) Approved in Canada for Treatment of Multiple Sclerosis
HSMN NewsFeed - 17 Sep 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada(TM) (alemtuzumab)
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 9 Dec 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
Teva Announces Successful Results of Phase III Study with Oral Laquinimod for Multiple Sclerosis
HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
HSMN NewsFeed - 24 Feb 2009
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
Merck Serono and Ambrx Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance
HSMN NewsFeed - 19 Feb 2009
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
European Medicines Agency Recommends Suspension of Marketing Authorization for Raptiva(R)
HSMN NewsFeed - 7 Nov 2007
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron(R) than with Rebif(R)
HSMN NewsFeed - 16 Jan 2007
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
HSMN NewsFeed - 20 Oct 2006
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
AVONEX(R), The #1 Prescribed Multiple Sclerosis Therapy Worldwide, Improves Patient Convenience
HSMN NewsFeed - 29 Sep 2006
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
AVONEX(R), the #1 Prescribed Multiple Sclerosis (MS) Therapy Worldwide: New MRI Data Presented
HSMN NewsFeed - 10 Jul 2006
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
European Commission Approves Revision of Therapeutic Indication for Rebif(R)
HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed - 19 May 2006
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
AVONEX(R), the Most Prescribed Multiple Sclerosis Therapy Worldwide, Celebrates 10th Anniversary
HSMN NewsFeed - 28 Apr 2006
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis
HSMN NewsFeed - 4 Apr 2006
Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe
Serono Submits New Formulation of Rebif(R) for Approval in the United States and in Europe
Additional items found! 60

Members Archive contains
60 additional stories matching:
interferon beta-1a
(Password required)
interferon beta-1a
(Password required)